Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Mini-Gene Therapy for Cystic Fibrosis

By Biotechdaily staff writers
Posted on 21 May 2002
Shortened versions of the normal cystic fibrosis transmembrane regulator (CFTR) can function like normal, full-length protein in experimental models of cystic fibrosis (CF) disease, according to researchers at the University of Iowa (UI, Iowa City, USA; www.uiowa.edu). More...
This finding may lead to strategies that could make gene therapy for CF a reality.

Despite the advantages of an adeno-associated virus (AAV) as a vector for gene therapy for CF, AAV is too small to accommodate the normal CFTR gene. The researchers made a series of mini-CFTR genes that produce shortened protein in airway cells by deleting parts of the CFTR protein from a region called the R domain. Two model CF cell systems were used to test the ability of the shortened proteins to act like normal, full-length CFTR in airway cells. The experimental models are designed to mimic airway cells in humans with CF. In both models, each mini-gene made protein with all the properties and function of the normal full-length protein. Additional studies are needed to generate an AAV vector that could prove useful in CF gene therapy.

"We proved that we could actually take out a fairly significant part of the domain without affecting the protein's ability to transport chloride ions and without affecting its ability to get to the right place in the cell to start working,” said Lynda S. Ostedgaard, Ph.D., UI associate research scientist in internal medicine and lead author of the study.

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.